Premium
Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas
Author(s) -
Mathé G.,
Schwarzenberg L.,
Pouillart P.,
Oldham R.,
Weiner R.,
Jasmin C.,
Rosenfeld C.,
Hayat M.,
Misset J. L.,
Musset M.,
Schneider M.,
Amiel J. L.,
De Vassal F.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197410)34:4<985::aid-cncr2820340402>3.0.co;2-u
Subject(s) - medicine , leukemia , lymphoma , acute leukemia , lymphoid leukemia
The preliminary results obtained with VM 26 and VP 16213 (two semisynthetic derivatives from epipodophyllotoxin) on leukemias and hematosarcomas are described. These compounds are phase M dependent, myelostatic agents whose toxicity can be controlled by intermittent administration. VM 26 proved capable of inducing regression in Hodgkin's disease, reticulosarcomas, and lymphosarcomas. Its most remarkable effect was the total regression of neoplastic pleural effusions by systemic administration. VP 16213 seemed to be effective on the same hematosarcomas, but less often. Its most striking action was its oncostatic effect in acute monocytoid leukemia and in the monocytoid component of acute myelomonocytoid leukemia.